Pharming Group Faces Investor Scrutiny After Revenue Guidance Cut
A 22% single-session plunge in Pharming Group shares on July 30 has triggered a securities investigation by Levi & Korsinsky. The sharp sell-off followed the company's decision to slash its full-year 2026 revenue forecast, marking a significant departure from the optimistic projections previously provided to the market.






















